A Prospective, Open-label, Single-arm, Clinical Study of Disitamab Vedotin Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple Upper Urinary Tract Urothelial Carcinoma
Latest Information Update: 12 Apr 2024
At a glance
- Drugs Disitamab vedotin (Primary) ; Toripalimab (Primary)
- Indications Carcinoma; Renal failure; Urogenital cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Apr 2024 New trial record